GeneOne Life Science, Inc. (KRX:011000)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,154.00
-58.00 (-4.79%)
Last updated: Mar 3, 2026, 11:33 AM KST
-48.60%
Market Cap 103.26B
Revenue (ttm) 30.90B
Net Income (ttm) -51.36B
Shares Out 85.20M
EPS (ttm) -627.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 888,720
Average Volume 2,752,514
Open 1,140.00
Previous Close 1,212.00
Day's Range 1,137.00 - 1,178.00
52-Week Range 1,137.00 - 4,270.00
Beta 0.72
RSI 23.13
Earnings Date Mar 18, 2026

About GeneOne Life Science

GeneOne Life Science, Inc., a biopharmaceutical company, engages in the research, development, and contract manufacturing of nucleic acid-based biopharmaceuticals. Its small molecule pipeline comprises GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, which is Phase II clinical trial for treatment of COVID-19. The company’s nucleic acid vaccines include GLS-3000 mRNA under feasible study and GLS-5310 DNA... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1976
Employees 41
Stock Exchange Korea Stock Exchange
Ticker Symbol 011000
Full Company Profile

Financial Performance

In 2024, GeneOne Life Science's revenue was 35.72 billion, a decrease of -11.15% compared to the previous year's 40.20 billion. Losses were -48.54 billion, -37.59% less than in 2023.

Financial Statements

News

There is no news available yet.